• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Base Metals Market
    Base Metals News
    Base Metals Stocks
    • Base Metals Market
    • Base Metals News
    • Base Metals Stocks
    lead investing

    5 Top Weekly TSX Stocks: LeadFX Surges on Hydromet Plant DFS

    Priscila Barrera
    Mar. 04, 2018 07:50PM PST
    Base Metals Investing
    Lead Investing

    Last week’s other top-gaining mining stocks on the TSX were Tahoe Resources, RNC Minerals, General Moly and Marathon Gold.

    The S&P/TSX Composite Index (INDEXTSI:OSPTX) was down last week, declining 1.79 percent to close the five-day period at 15,363.55.

    The index edged down in early trade on Friday (March 2), as financial, industrial and energy shares declined.

    On Friday, the gold price rebounded after touching a two-month low the previous session. Base metals were also down for the week, with LME copper on track for a weekly loss.

    Despite those factors, a number of stocks in the mining sector saw share price increases last week. The five top gainers are as follows:

    • Tahoe Resources (TSX:THO)  
    • LeadFX (TSX:LFX)
    • RNC Minerals (TSX:RNX)  
    • General Moly (TSX:GMO)
    • Marathon Gold (TSX:MOZ)

    Here’s a look at those companies and the factors that moved their share prices last week.

    1. Tahoe Resources

    Tahoe Resources is focused on the exploration, development, operation and acquisition of mineral properties for the mining of precious metals in the Americas.

    The company has no recent news that would explain its share price increase, but over the five-day period it saw a spike of 24.4 percent to close at $6.27.

    2. LeadFX

    LeadFX is focused on the development of lead–silver projects located in Australia and North America. The company’s flagship asset is the Paroo Station lead mine, located 30 kilometers west of the town of Wiluna in Western Australia. The company also owns an 83.5-percent interest in the Burin mines and surrounding land claims in the Tintic Mining District 60 miles southeast of Salt Lake City, Utah.

    Last Thursday (March 1), the company announced the results of a definitive feasibility study for Paroo Station. Over the five-day period, shares of LeadFX gained 21.62 percent to reach $1.80.

    3. RNC Minerals

    RNC Minerals is a multi-asset precious and base metals mining company. The company’s principal assets are the producing Beta Hunt gold-nickel mine in Western Australia, the Dumont nickel–cobalt project in the established Abitibi Mining Camp in Quebec and a 30-percent stake in the producing Reed mine in the Flin Flon-Snow Lake region of Manitoba.

    The company announced value enhancement initiatives for its Dumont mine last Thursday. Over the five-day period, RNC Minerals saw a spike of 14 percent to close at $0.28.

    4. General Moly

    General Moly is engaged in the exploration, development and mining of molybdenum assets. General Moly owns an 80-percent interest in the Mount Hope project and 100 percent of the Liberty project, both of which are located in Nevada.

    Last Friday (March 2), the company announced a progress update on its projects. Over the five-day period, General Moly saw a spike of 8 percent to close at $0.54.

    5. Marathon Gold

    Last but not least is Marathon Gold, a company currently advancing its Valentine Lake Gold Camp in Newfoundland, which hosts four near-surface, mainly pit-shell constrained gold resources. Shares of Marathon Gold saw an increase of 7.69 percent last week to reach $0.98.

    Don’t forget to follow us at @INN_Resource for real-time news updates!

    Data for 5 Top TSX Stocks articles is retrieved each Friday at 10:30 a.m. PST using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $50 million prior to the week’s gains are included. Companies within the mining and precious metals sectors are considered.

    Securities Disclosure: I, Priscila Barrera, hold no direct investment interest in any company mentioned in this article.

    lead investingaustraliaglobe and maillme coppergeneral moly
    The Conversation (0)

    Go Deeper

    AI Powered
    silver bars and coins on top of charts

    5 Top Weekly TSX Performers: Alexco Surges on Hecla Acquisition

    Coal Investing

    5 Top TSX Stocks: Lithium Americas Leads the Way

    Latest News

    Nine Mile Metals Announces Certified High-Grade Assay Results up to 15.00% Copper from the Wedge Project, Bathurst, New Brunswick

    International Lithium Corp. Updates on Lepidico Arbitration Determination

    Managing Director Resignation and Board Changes

    Steadright Grants Stock Options

    Copper Quest Closes Second and Final Tranche of Flow-Through Private Placement

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Base Metals Investing Stocks

    Ardelyx Inc.

    Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

    IMARA Inc.

    Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9.

    Astria Therapeutics Inc.

    Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

    Turning Point Therapeutics Inc.

    Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

    Biomea Fusion Inc.

    Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

    Acumen Pharmaceuticals Inc.

    Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES